These findings support ongoing clinical trials for mobocertinib (NCT02716116) and suggest that lung adenocarcinoma patients with a HER2 exon-20 A775_G776insYVMA mutation could potentially be treated with a combination of mobocertinib and T-DM1 [127]. Here, ERBB2 is linked to lung adenocarcinoma.